6505--Tacrolimus Capsules

The Department of Veterans Affairs National Acquisition Center has issued a solicitation for Tacrolimus Capsules under RFP 36E79725R0057, seeking to establish a pharmaceutical contract for three different strengths of this immunosuppressive medication: 0.5mg, 1mg, and 5mg capsules, each packaged in 100-capsule bottles. The contract structure includes a base year with four one-year option periods, serving multiple federal agencies including the VA, Department of Defense, Indian Health Service, and Bureau of Prisons. Offerors must provide comprehensive pharmaceutical manufacturing qualifications including FDA approvals, unique NDC numbers, and compliance with Drug Supply Chain Security Act requirements, along with meeting specific packaging standards and bar coding specifications. The solicitation originally had a closing date of September 30, 2025, but has been extended through Amendment 0001 to October 9, 2025, at 2:30 PM Central Time. All offerors must submit pricing for all line items and option years, including a mandatory 0.5% Cost Recovery Fee, and the government plans to make one aggregate award.

This procurement is unrestricted with no set-aside designation, though it operates under a small business size standard of 1,300 employees for the Pharmaceutical Preparation Manufacturing NAICS code 325412. The estimated annual requirements vary significantly by strength, ranging from 5,207 bottles for certain formulations to 142,788 bottles for others, reflecting the diverse needs across the federal healthcare system. Distribution of the awarded products will be handled through Pharmaceutical Prime Vendors, specifically mentioning McKesson Corporation as part of the distribution network. The contract falls under PSC category 6505 for Drugs and Biologicals, and the procurement follows standard federal acquisition procedures with all original solicitation terms and conditions remaining unchanged except for the extended deadline. Performance will likely involve manufacturing and supplying these critical immunosuppressive medications to federal healthcare facilities nationwide through the established prime vendor distribution system.